Physician attitudes about genetic testing for localized prostate cancer: A national survey of radiation oncologists and urologists
Prostate cancer is a highly prevalent male malignancy with approximately 180,000 diagnosed and 30,000 dying each year in the United States [1]. Due to the indolent natural history of prostate cancer, greater emphasis is now placed on shared decision-making and active surveillance to address concerns about overtreatment [2]. Effective treatment decision-making for localized prostate cancer therefore requires accurate predictive tools to best quantify clinical aggressiveness and risk of cancer-related morbidity and mortality at the time of diagnosis [3,4].
Source: Urologic Oncology: Seminars and Original Investigations - Category: Urology & Nephrology Authors: Simon P. Kim, Neal J. Meropol, Cary P. Gross, Jon C. Tilburt, Badrinath Konety, James B. Yu, Robert Abouassaly, Christopher J. Weight, Stephen B. Williams, Nilay D. Shah Tags: Original article Source Type: research
More News: Cancer | Cancer & Oncology | Genetics | Prostate Cancer | Urology & Nephrology | USA Health